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Abstract 
Studies indicate that many tumors overexpress normal self-proteins.  Multiple 
regulatory mechanisms of the body minimize the immune response to antigens perceived 
as self allowing the unregulated growth of cancerous cells expressing self-proteins.  
Different from active immunization for infectious diseases, which triggers an immune 
response to foreign antigens, vaccination for cancer treatment and prevention often 
targets antigens that are perceived by the immune system as native, and therefore must be 
capable of circumventing the bodys defenses.  HER-2 (Human epidermal growth factor 
receptor-2) is a self-protein overexpressed in 20-30% of breast, as well as, ovarian, lung, 
stomach, bladder, and salivary cancers.   HER-2 is a member of the ErbB family of 
receptors, which convey signals by homo- or heterodimerization of the extracellular 
domain. Dimerization causes transphosphorylation of the receptors, which triggers 
downstream signaling and results in increased development, proliferation and 
differentiation of cells.  The overexpression and the preference of HER-2 as a 
dimerization partner make it an ideal target in cancers for active and passive 
immunotherapy.  Active immunization with tumor vaccines can be used to employ the 
patients own immune system to destroy mammary tumor cells, leading to sustained anti-
tumor resistance due to immunological memory, which would eliminate the requirement 
for continual, repetitive cycles of therapy.  In this study, the specific HER-2 B-cell 
epitope evaluated was the extracellular dimerization loop region.  The specific HER-2 B-
cell epitope was co-linearly synthesized with the promiscuous T-helper epitope MVF 
(288-302), which originated from the measles virus fusion protein (MVF).  The B-cell 
and promiscuous T- cell epitopes were connected by a flexible four-residue turn (GPSL) 
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allowing the B-cell and T-cell epitopes to fold independently.  A portion of the B-cell 
epitope synthesized was altered to form a disulfide bond between two cysteines to mimic 
the structure of the native HER-2 receptor dimerization region, giving a cyclized (Cyc) 
construct (containing the disulfide bond) and a linear (NC) construct.  These rationally 
designed peptide vaccines were analyzed for their ability to induce antibodies with anti-
proliferative capabilities.  Both epitopes induced high-titered antibodies in outbred 
rabbits.  Analysis by flow cytometry revealed antibody recognition and binding of the 
native HER-2 protein in human HER-2 overexpressing BT-474 cells, as well as the rat 
neu homolog of human HER-2 in mouse NT2.5 cells.  These antibodies caused antibody-
dependent cell mediated cytoxicity of HER-2 positive breast cancer cells in vitro.    
Passive and active immunotherapeutic experiments were carried out in transgenic mice.  
Inbred Neu2-5+/- mice vaccinated with the target peptide showed delayed onset of tumor 
development and a decrease in tumor volume.  Double transgenic (VEGF+/- Neu2-5+/-) 
mice were tested by passive immunotherapy due to rapid tumor onset in these mice.  
VEGF+/- Neu2-5+/- mice injected with peptide antibodies had smaller average sized 
tumors demonstrating the ability of the induced antibodies to inhibit HER-2-dependent 
proliferation and dimerization.  These synthetic peptide vaccines have therapeutic 
potential to elicit antibodies that will successfully prevent or limit the growth of HER-2 
overexpressing cancers. 
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Chapter 1 
Introduction 
 
1.1 Cancer Issue 
 The second leading cause of death in the United States is cancer.  In 2003, there 
were 556,902 deaths due to cancer which contributed to 22.7% of all deaths that year. 
Cancer contributes $180 billion in direct medical costs and one out four deaths is due to 
cancer (1).  Four of the most common cancers account for over 50% of the estimated new 
cases in the US in 2006 (Table 1).  The prognosis for cancer patients is not hopeless; 
there were nearly 9 million people living in the United States in 1999 who survived 
cancer (1).   
 
Types of Cancer                     Estimated number of                        Estimated deaths 
            new cases (both sexes) 
Breast                                       214,640                                               41,430 
Prostate                                    234,460                                               27,350 
Lung and bronchus                  174,470                                             162,460 
Colon                                  106,680                                         55,170 
Stomach                                22,280                                         11,430 
Ovarian                                 20,180                                         15,310 
       Source: American Cancer Society, Cancer Facts & Figures 2006         
(http://www.cancer.org/downloads/stt/CAFF06EsCsMc.pdf) 
 
Table 1.1.  Estimated new cases of cancer and deaths in 2006 in the U.S. The first four are the most common cancers.  
HER-2 overexpression found in all. 
 
This suggests that current treatments are effective; however the options that exist such as 
chemotherapy, surgery, and radiation therapy have detrimental and debilitating side 
effects. 
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1.2 Current Cancer Treatment 
 Cancer occurs as a result of cells that continually divide and grow without normal 
control.   Cancer treatments are used to remove, control or kill the abnormal growing 
cells.  Some treatment options for cancer that exist now include chemotherapy, surgical 
resection and radiation therapy.   
 
Chemotherapy 
 Chemotherapy is a treatment for cancer that uses powerful drugs to stop abnormal 
cancerous cell growth.  Because cancer cells divide frequently they are more sensitive to 
chemotherapy treatment than normal cells.  However, rapidly dividing healthy cells such 
as skin cells and normal blood cells can be affected by chemotherapy.  The harmful side 
effects from this treatment arise when healthy cells are destroyed along with the 
cancerous cells.  Chemotherapeutic agents can cause a decrease in red blood cells that 
carry oxygen to the lungs, white blood cells that fight infections and platelets that help 
blood clot.  A low red blood cell count results in anemia, which causes one to feel tired 
and short of breath.  When the white blood cell count is low, it is hard for the body to 
fight infections this condition is known as neutropenia.  A decrease in platelets results in 
thrombocytopenia.  This condition can result in excessive external and internal bleeding, 
which can result in strokes or death. 
 
Surgical Resection 
 Curative surgery is a procedure used to remove a tumor that is confined to one 
area.  A problem with this method of treatment does not ensure that all of the tumor will 
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be removed.  There are different risks associated with surgery.  Possible risks include 
excessive bleeding, which may require blood transfusion, and damage to internal blood 
vessels or organs.  Problems with major organs such as the heart, lungs or kidneys can 
occur and become life-threatening.   After surgery pain and infection are common side 
effects, but are usually not life threatening.  Some long-term side effects occur as a result 
of specific surgical procedures.  For example, men undergoing prostatectomy (removal of 
the prostate) sometimes lose control of urination or become impotent. 
 
Radiation Therapy 
 Radiation therapy is the treatment of cancer with X-ray or other radiation beams.  
It is used to treat localized solid tumors.  Ionizing radiation delivers energy to and 
destroys the target tissue (cancer) by damaging the genetic material, thus stopping cell 
growth.  The risk involved is that radiation damages both normal and cancerous cells.  
However, normal cells are able to repair themselves and function properly.   Aside from 
carcinogenic characteristics of radiation, side effects of this treatment include nausea, 
hair loss, genetic effects and low blood count.  Genetic effects include abnormal changes, 
mutations and failure to reproduce.  Radiation can directly damage lymphocytes in the 
blood stream, which are important components of the bodys immune system 
 
1.3 Cancer Research 
The failure of current treatments is generally due to the rapid growth of tumor 
cells that are resistant to standard treatments.  These observations demonstrate the need 
for a different approach that can overcome or circumvent the resistance mechanisms of 
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tumor cells to standard treatments.   Maximizing cancer treatment by using the hosts 
immune system is a highly attractive alternative approach to disease management.   
Studies indicate that many tumors overexpress normal self-proteins. HER-2/ neu 
(human epidermal growth factor 2), a growth factor receptor, is overexpressed in 30% of 
breast cancers as well as, ovarian, lung, colon, stomach and prostate cancers (see Table 
1.1)(2).  The idea of vaccination against such cancers was derived from the detection of 
weak immune responses in cancer patients who overexpress self-tumor antigens.  Thus 
these antigens (HER-2/neu) have become excellent targets for active and passive 
immunotherapies. 
Passive immunotherapeutic strategies include the transfer of antigen-specific T 
lymphocytes and the injection of monoclonal antibodies that target a specific tumor 
antigen.  Traztuzumab (Herceptin) is a monoclonal antibody specific for HER-2/neu, as a 
passive immunotherapeutic it is effective against the biologically distinct set of breast 
cancers that overexpress HER-2/neu oncoprotein (3).  Active immunization with tumor 
vaccines can be used to employ the patients own immune system to destroy mammary 
tumor cells.  The theoretical advantage of active immunization is the potential for 
sustained anti-tumor resistance due to immunological memory, which would eliminate 
the requirement for continual, repetitive cycles of therapy. 
Different  from active immunization for infectious diseases, which triggers an 
immune response to foreign antigens, vaccination for cancer treatment and prevention 
often targets antigens that are perceived by the immune system as native (3).  Therefore, 
multiple regulatory mechanisms of the body minimize the immune response to antigens 
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perceived as self.  In order to develop an effective cancer vaccine it is vital to form 
strategies for circumventing such immune tolerances. 
 
Clinical Trials 
Trastuzumab and pertuzumab are recombinant humanized monoclonal antibodies 
that target different regions on the extracellular domain of HER-2. Trastuzumab is 
directed against the extracellular subdomain IV of the HER-2 tyrosine kinase receptor.  
Clinical studies have shown trastuzumab (Herceptin) to be active against HER-2 
overexpressing breast cancer, leading to its FDA approval (Fig.1.1) (4).  Current 
treatment protocols combine trastuzumab with other drugs to successfully increase time 
to tumor progression, and survival of patient.  Pertuzumab is currently undergoing Phase 
II clinical trials in cancer patients with solid tumors.  Pertuzumab sterically hinders HER-
2 dimerization with other HER-receptors and effectively blocks ligand-activated 
signaling from the HER-2/HER-1 and HER-2/HER-3 heterodimers (Fig. 1.1) (4).   
 
Fig.1.1. Schematic diagram of Trastuzumabs blockage on subdomain IV and of Pertzumabs blockage on 
subdomain II of HER-2 (ERBB2). Source http://www.medscape.com. 
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Trastuzumab and pertuzumab in combination effectively inhibited HER-2 positive 
cell (BT474) survival, partly because of increased apoptosis (4).  Trastuzumab augments 
pertuzumab mediated interference of HER-2 dimerization with HER-3.  The combined 
drug treatment reduced levels of total HER-2 and of phosphorylated HER-2 protein, and 
it also inhibited receptor signaling.  This suggests that an effective therapeutic strategy 
for breast caner would involve a combination of HER-2 targeting agents as opposed to 
treatment with a single HER-2 monoclonal antibody (4). 
 
HER-2 Background 
In normal cells, activation of the HER-2 receptor family starts a network of 
signaling pathways that control normal cell growth, differentiation, motility and adhesion 
in several cell lines.  Studies have shown the crucial role of the HER receptor family in 
development of the cardiovascular system and the nervous system(5).  HER-2 is a 
transmembrane phosphoglycoprotein that is the product of the epidermal growth factor 
receptor B-2 (erbB-2) gene (Fig.1.1).    
 
Fig. 1.2. Three-dimensional structure of the human epidermal growth factor 2 (HER-2) protein monomer 
with subdomains I-IV labeled.  Picture from Protein Databank http://www.pbd.org. 
 
Ι
ΙI 
ΙII
ΙV
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It is the human version of the rat oncongene neu.  HER-2 is classified as an epidermal 
growth factor receptor (EGFR/erbB-1) family member.  The ErbB family members and 
their ligands are present in eukaryotic organisms and have been involved in different 
cancers because of dysregulation or mutation of the ErbB genes (5).  The extracellular 
domain (ECD) consists of multiple glycosylation sites and is very cystein-rich.  The 
intracellular domain contains a highly conserved tyrosine kinase (6).  The ErbB family 
members ErbB1(HER-1/EGFR), ErbB2 (HER-2), ErbB3 (HER-3)  and ErbB4 (HER-4) 
have ligand binding extracellular regions that consists of four domains (I, II, III, and IV) 
as well as a number of tyrosine phosphorylation sites on a C-terminal tail (with varying 
length dependent on the family member).  The tyrosine phosphorylation sites serve as a 
platform for connecting molecules and enzymes to facilitate downstream signaling (7).   
There are about a dozen known ligands that bind mammalian ErbBs.  Structural 
comparisons of ErbB3 monomer and the EGFR ligand-bound dimer have shown that the 
ligand binds at a site between domains I and III, and this has been shown in ErbB4 as 
well (8)(Fig.1.3b).  This binding results in a conformational change in the receptor ECD 
(9).  However, HER-2 is the only ErbB family member for which no ligands have been 
found.  The structure of the ECD of HER-2 reveals a closed binding site where positions 
in domains I and III are in direct contact with each other (10) (Fig.1.3).  Therefore, the 
binding site residues present in the rest of the ErbB family is no longer conserved in 
HER-2 indicating that HER-2 is incapable of ligand binding.   
Ligand-induced dimerization permits normal downstream signaling for the ErbB 
family (11) (Fig.1.3).  In the absence of a ligand, the extracellular domain of EGFR, 
ErbB3, and ErbB4 has a β hairpin loop in domain II that contacts a region of domain IV.  
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This is designated as the closed confirmation (8).  In the open form the domain II β 
hairpin extends outward from the body of the molecule, and is involved in most of the 
contacts seen in the EGFR dimer (Fig.1.3b ) (11).  HER-2 is always in an open 
confirmation (10), which gives a possible reason as to why it is the favored dimerization 
partner of the other ErbB family members (12).   
 
 
 
 
Fig. 1.3. Dimerization process of HER-2 and HER-3 (ERBB3). a.HER-2 and the closed confirmation of 
HER-3 b. Ligand (NRG) bound HER-3 in open form.  c. Dimerization of HER-2 with opened HER-3.  
Source http://www.medscape.com. 
 
Dimerization allows the intracellular kinase domains of the two ErbBs to associate 
intimately, thus stimulating tyrosine kinase activity and resulting in transphosphorylation 
of tyrosine residues on the C-terminal tail of one ErbB by the others kinase domain (7).  
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The phosphorylated residues serve as a scaffold for signaling molecules involved in the 
regulation of intracellular signaling cascades (13).  These cascades play roles in 
development, proliferation and differentiation in a variety of tissues where ErbB 
receptors are present. 
 
 Mouse Model of Human Cancer 
 Most of the genetic changes observed in human breast cancer can be categorized 
as: 1) gain of function mutations in genes (proto-oncogenes) that are involved in cell 
growth, division and survival or 2) loss of function mutations in tumor suppressor 
genes responsible for regulating unrestrained cellular growth.  Genetically engineered 
mouse (GEM) models of human cancers are developed by modifying the mouse genome 
to dysregulate the expression of a specific gene in targeted tissues or by introducing 
specific genetic mutations that change gene function, causing tumor development (14).  
These mouse models help to assess potential cancer preventative methods in vivo.  Such 
screenings are important steps towards the selection of methods for clinical trials in 
humans.  These studies have defined the biological functions of hundreds of genes and 
have provided insight into many aspects of cancer research (15).   Mouse models have 
been used to test cancer vaccines, target therapies, preventative agents and combinations 
of chemopreventive and/or therapeutic agents (14).  
 
Neu2-5+/- Mouse Models 
 Several mouse models have been developed for specifically testing HER-2 
overexpressing tumor growth.  A majority of these models use the MMTV promoter to 
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overexpress the neu protein resulting in mouse mammary tumors similar to human breast 
cancer.  Transgenic mouse models have shown that the rat proto-oncogene HER-2/neu, 
with an amino acid change in the extracellular domain is highly tumorigenic in mice (5).  
The transgene is expressed in the mammary and salivary glands of female mice and in the 
salivary and reproductive organs in males.  These transgenic mice show a late onset of 
mammary tumors that is restricted to females.  The Neu2-5+ mice develop spontaneous 
tumors around the age of 177 days.    
 
VEGF+/- × Neu2-5+/- Mouse Models 
 HER-2 signaling leads to the increased expression of VEGF, an angiogenic (new 
vessel formation) factor.  Double transgenic mice (VEGF+/- Neu2-5+/-) have accelerated 
tumor development around the age of 56 days due to the combination of VEGF and neu 
proteins in mammary tissue.  The two transgenes have been found to have overlapping 
expression patterns. 
 
Advantages and Disadvantages of Transgenic Mouse Models 
Advantages: 
 There are many advantages in developing such models for human cancers.  These 
models progressively develop tumors in stages, while also interacting with the 
surrounding tissues.  Like in humans, metastasis occurs in the presence of a working 
immune system (16). There are histological similarities between the mammary tumors in 
mice and human breast cancer(14), and many of the mouse tumors that develop are 
hormone independent, like human breast cancers. 
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Disadvantages: 
 Most transgenic females can not carry and support babies, which requires the use 
of non-transgenic females as breeders.  This results in a 25% chance of getting transgenic 
females that are expected to develop tumors.  Lack of mutation in human breast cancers 
suggests that the primary cause is due to over-expression of the wild-type HER-2/neu and 
not mutational activation, which is used in mouse models. Despite the 88% homology 
(similarity in structure and function) of human and rodent HER-2/neu, the monoclonal 
antibody Pertuzumab only has affinity for the human HER-2/neu and not the rodent 
homolog.  
 
1.4 Value of an Immunotherapeutic Approach 
Surgical excision or ablations by use of radiation are primary cancer treatments 
that work for some patients.  However, for other patients relapses are common and 
tumors may reoccur at the same site or metastasize to different sites.  For this reason, 
preventative measures have become a popular area in clinical oncology in recent years.  
Different studies have shown that the cellular and the humoral branches of the immune 
system are capable of generating an antigen specific response against tumor antigens.  
There is a vast array of potential advantages affiliated with active immunization as 
opposed to current chemotherapy and radiation therapy.  A key advantage is the 
specificity that is offered by active immunotherapy.  Specificity leads to tumor rejection 
with fewer side effects that include autoimmunity.  Another advantage of active specific 
immunotherapy is the production of an immunological memory, which is not associated 
with passive treatments such as the introduction of antiviral or anti-tumor antibodies.  
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The subject of this thesis is the design and application of synthetic peptide based vaccines 
in the treatment or prevention of cancer. 
 
1.5 Synthetic Peptides as Vaccines for Cancer 
Cancers such as breast, ovarian and skin are due to the overexpression of normal 
growth regulatory proteins, known as tumor antigens (2).  The concept of designing 
vaccines that target such cancers comes from the detection of weak immune responses in 
cancer patients against self-tumor antigens.  For instance, patients who overexpressed the 
self-protein HER-2 in their cancers demonstrated both humoral (B-cell) and T-cell 
immune responses (2).  Therefore, it is hypothesized that constructing vaccines to 
stimulate the already present immune response could aid in the treatment of cancer by 
enhancing the hosts immunity to the specific tumor antigen. 
 
T-Cell Vaccines 
 Cancer researchers have largely focused their efforts on vaccines designed to 
trigger cytotoxic T-cell responses.  T-cells (T-lymphocytes) target and attack infected 
foreign or cancerous cells in the body.  They also help regulate other immune responses 
by signaling other defenders in the immune system. The rationale behind this focus 
mainly stems from the belief that a cell-mediated immune response is the most promising 
mechanism for controlling viral replication and destroying tumor cells.  Cell based 
vaccination using either allogenic (genetically different but from same species) or 
syngenic (genetically identical) tumor cells expressing rat neu have been shown to elicit 
T-cell and antibody responses in mice (2).  However, a disadvantage to using cell-based 
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vaccines is their potential to cause complex immune responses that can result in tolerance 
or hypersensitivity and the additional complications from auto immune reactions.   
 
B-Cell Vaccines 
 There is evidence that humoral immune responses (antibodies) are probably 
intimately involved in controlling tumor growth.  B-lymphocytes (B-cells) mature into 
antibody (immunoglobulin) secreting plasma cells. Antibodies recognize and bind to 
foreign substances known as antigens.  Each type of B-cell is unique and makes one 
specific antibody that recognizes one specific antigen, like a lock and key.  B-cell 
vaccines stimulate the immune system in an attempt to indirectly eliminate cancerous 
cells by marking them for destruction. 
 
1.6 Project Overview 
The immune system is a complex network of cells; organs that operate together to 
protect the body from foreign or non-self antigens. The immune system works to fight 
disease and cancer by differentiating between healthy and non-healthy (i.e. cancerous) 
cells in the body and working to destroy the cell that become cancerous (Fig.1.3).  When 
the immune system is not functioning properly or breaks down cancer can occur. 
Immunotherapy is designed to stimulate the bodys immune system to directly or 
indirectly fight cancer and lessen or eliminate detrimental side effects experienced by 
most cancer treatments.   
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Fig.1.4 Immune system responses to antigens. Source: Cellular and Molecular Immunology, Abbas 
There are compelling discoveries that support the significance of the humoral immune 
responses (antibodies) in controlling tumor growth.  This approach to immunotherapy 
involves passive injection of humanized monoclonal antibodies.  Antibody based 
approaches are supported by tumor regressions observed in cancer patients given 
Herceptin (humanized monoclonal antibody).  Other anticancer antibodies like 
pertuzumab and bevacizumab are presently in phase II and III clinical trials. 
The focus of this thesis is to develop a peptide vaccine that can stimulate both 
cell-mediated and humoral immune responses including antibodies and helper T-cells.  
Antibodies have an affinity to certain regions in proteins on tumor cell surfaces.  A 
vaccine design that targets a portion of the protein rather than the whole protein domain 
of the antigen may prove effective in circumventing the immune tolerance of the native 
protein.  The rational for subunit peptide-based vaccines comes from studies showing that 
immunizations of rats with multiple T-helper peptides derived from the rat neu protein 
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elicited strong humoral and CD4+ (T-helper cell) responses, whereas immunizations with 
purified whole rat neu protein failed to cause detectable immune responses (17). 
We hypothesized that a subunit peptide-based vaccine targeting a specific B-cell 
epitope on the HER-2 extracellular domain could induce antibodies capable of inhibiting 
the growth of HER-2 overexpressing cancers.
 16 
 
Chapter 2 
Material and Methods 
 
2.1 Rationale of Peptide Construct 
B-cell Epitope Selection 
The selection of the B-cell epitope located within the human HER-2 extracellular 
domain was accomplished by analysis of a 3.2 angstrom X-ray picture of HER-2 in 
complex with pertuzumab(18) (Fig2.1).  
 
Fig.2.1 Pertuzumab complexed with HER-2 proteins extracellular subdomain II. 
 Pertuzumab is an anti-HER-2 monoclonal antibody that is currently used in clinical trials 
to treat HER-2 overexpressing cancers.    
 
2.2 Peptide Construct Synthesis and Purification 
Peptide Synthesis and Purification 
B-cell epitope HER-2 pertuzumab loop was co-linearly synthesized with a 
promiscuous TH epitope (MVF) derived from the measles virus fusion protein (amino 
acids 288-302) (Fig.2.2).  Peptide synthesis was performed on a Milligen/Biosearch 9600 
solid-phase peptide synthesizer (Bedford MA) using a Fmoc/t-But chemistry.  Preloaded 
Pertuzumab 
HER-2 
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Fmoc-Val-CLEAR ACID resin (0.36 meq/g) (peptide International, Louisville, KY) was 
used for the peptide synthesis using PyBop/HoBt coupling method.  The B-cell epitope 
was assembled by choosing regioselective side chain protection on Cys residues as: 
Cys(trt) (19).  Also, MVF TH epitope with four residue linker (GPSL) was incorporated 
for independent folding and was assembled on B-cell epitope.  All peptides were cleaved 
from the resin using global deprotection reagent B (TFA: Phenol: Water: TIS, 90:4:4:2).  
The protecting group from Cyc (Trt) comes off in the global cleavage reaction as 
confirmed by electrospray ionization mass spectroscopy (ESI-MS) analysis at the 
Campus Chemical Instrumentation Center, The Ohio State University Columbus, Ohio.  
Crude peptides were purified on preparative RP- HPLC using C-4 vydac column in 
water: acetonitrile (0.1%TFA) gradient system.  Pure fractions were analyzed using 
analytical HPLC, pooled together and lyophilized in 1% acetic acid solution.   
          
Fig.2.2. MVFHER-2 pertuzumab loop chimeric peptide constructs a. Non-cyclized (NC) linear construct b. 
Cyclized (Cyc) construct 
 
Disulfide Pairing of Cyclization 
 Intramolecular disulfide bonds were formed using iodine oxidation as reported by 
(20) (Fig.2.3).  Linear peptide was generated by dithiothreitol (DTT) reduction.  Cyclic 
HOOC 
HER-2 (pertuzumab loop)  
G
S
L 
MVF 
P
NH2 
a. 
NH2
HOOC
G
L
S
P
MVF 
b.
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and linear peptides were further purified by semi-preparative RP-HPLC and characterized 
by electrospray ionization mass spectroscopy (ESI-MS). Disulfide bond formation was 
confirmed by PEO-maleimide reaction (Fig. 2.3).   
Fig. 2.3 Disulfide pairing between twp cysteines and malimide treatment after synthesis of MVFHER-
2(pertuzumab loop) Cyc and NC (see Fig2.2). (J.Peptide Sci. 6:387) 
 
2.3 Characterization of Peptide Construct 
Mass Spectrometry  
 The purified peptides were identified by electrospray ionization spectrometry 
(Campus Chemical Instrumentation Center, Ohio State University, Columbus,OH).   
 
Circular Dichorism (CD) Measurements 
 The CD spectra of both peptides were obtained on an AVIV model 62A DS CD 
instrument.  The spectral measurements were taken at 25ºC and under continual nitrogen 
purge of the sample chamber, using a 0.1-cm path length quartz cuvette.  Each peptide 
H2N-MVF-GPSL- Pertuzumab Loop-Resin
 SH        SH 
  |           | 
H2N-MVF-GPSL-Pertuzumab Loop-COOH
 Trt        Trt
  |           | 
TFA:Phenol:H20:TIS 
   |             |
H2N-MVF-GPSL-Pertuzumab Loop-COOH
AcOH,I2
Maleimide PEO2-Biotin H20 12h 
       S-PEO        S-PEO
        |                | 
H2N-MVF-GPSL-Pertuzumab Loop-COOH
Maleimide PEO2-Biotin H20 12h Disulfide bridge 
   |             |
H2N-MVF-GPSL-Pertuzumab Loop-COOH
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was dissolved in water and concentrated at 25µm, 50 µm, 75µm, and 100µm.  The mean 
residue ellipticity ([θ]), which is recorded in (deg cm2 / dmole), was calculated according 
to the equation: [θ] = (millidegrees)/ [10 x (l) x (n) x (c)].  Here n is the number of amino 
acids in the peptide, c is the peptide concentration in molarity, and l is the path length of 
the cuvette.  The circular dichroism (∆ε) = [θ]/ 3298. The helicity of each peptide was 
calculated according to Chen et al.,1969, which uses the mean residue ellipticity of 
polylysine for 100% α-helix θ222 = -35,700 as a reference.  Therefore, the actual percent 
helicity is calculated as follows:  %helicity = [θ]222/ XHn  where XHn is the max helicity 
and XHn = XH∞ (1- K/n).  XH∞ is the ellipticity for 100% helix of a chain of infinite 
length, and K is a wavelength dependent constant (2.57 at 222nm). 
 
Cross Reactivity ELISA 
 Six columns of 96-well plates were coated with 100µL of 2µg/mL peptide 
solutions of MVFHER-2 (pertuzumab loop) Cyc or NC in 1X PBS and the remaining 
four columns were coated with the matching B-cell epitope HER-2 (pertuzumab loop) 
Cyc or NC and refrigerated overnight at 4°C.  Serum dilutions, starting at 1/8000 of the 
cyclized antibodies were tested against the non-cyclized peptide and serum dilutions of 
the non-cyclized antibodies were tested against the cyclized peptide.  The plates were 
then developed as described above. 
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2.4 Immunogenicity 
   Peptide Immunization  
Female New Zealand White rabbits, FVB/n and BALB/c mice were used to 
obtain antibodies.  Two rabbits per peptide were immunized subcutaneously per peptide 
at multiple sites with a total of 1mg of each chimeric peptide in 100µg nor-MDP adjuvant 
and emulsified (50/50) in ISA 720.  Additional booster injections were given every 3 
weeks after the primary immunization with 1mg of peptide and 100µg nor-MDP adjuvant 
for 12 weeks.  Rabbit serum was collected every week and complement was inactivated 
by incubation for 30minutes at 56º C.  High-titered sera was purified on a protein A/G-
agarose column (Pierce, Rockford,IL), and eluted antibodies were concentrated in PBS.  
The antibody concentration was elucidated by the Commasie plus protein assay reagent 
kit (Pierce).   
 
Direct Enzyme Linked Immunosorbent Assay (ELISA) 
The 96-well plates were coated with100µl of a 2µg/ml concentration of antigen in 
PBS and refrigerated over night at 4ºC.  Wash buffer used was PBT/HS, (100mL of 10X 
PBS, 0.50mL Tween 20, 10mL Donor Herd Horse Serum and was brought up to 1L with 
ddH2O).  Plates were washed with PBT/HS and non-specific binding regions were 
blocked for 1 hour with 200µl of PBS/1%BSA and 0.02% sodium azide.  Plates were 
washed, then 200µl of serum dilution starting at 1/4000 was added to the antigen-coated 
plates in duplicate wells, and serially diluted 1:2 in PBT/HS wash buffer.  The plates 
were then incubated for 2 hours at room temperature.  After washing, 100µl of a 1/500 
dilution in PBT/HS of Pierce goat-anti-rabbit IgG with horse radish peroxidase was 
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added as a marker to each well and incubated for 1 hour.  The plates were washed with 
PBT/HS and water, afterwards 50µl of substrate solution (50µl of 30% H2O2, 10mL of 
citrate phosphate buffer with 0.5mg/ml 2,2-aminobis (3-ethylbenzthiazoline-6-sulfonic 
acid) as the chromophore) was added to each well for bound antibody detection.  The 
plate was then incubated for 10minutes in the dark at room temperature.  The reaction 
was stopped by adding 25µl of 1% SDS to each well.  The absorbance was read at 415nm 
on a BioRad microplate reader.  Titers were defined as the highest dilution of sera with 
an absorbance reading of greater than 0.2 excluding the background. 
 
2.5 Cell Culture 
All cell lines were kept according to the manufactures guidelines.  Both HER-2 
overexpressing and normal human cell lines were used, as well as, Neu+ and Neu- mouse 
cell lines (Table.2.1). 
 
Cell-line                    Human Cells          Mouse Cells        HER-2+                 Neu +         
                                                                                                    levels                     levels                                                                  
BT474                              Yes         No                   High                        -   
SK-BR-3                          Yes                        No                     High                        - 
                                MDA-468                        Yes                        No                     Normal                    - 
                             MCF-7                         Yes                     No                  Normal 
                             NT2.5                           No                     Yes                      -                      High 
  TUBO                           No                     Yes                      -                      High  
                TS/A                            No                      Yes                      -                      Low  
         
Table.2.1. Cell line characteristics. 
 
 
HER-2 overexpressing cancer cell lines 
 
BT-474 
 BT-474 is a human breast adenocarcinoma cell line that overexpresses the HER-2 
protein.  These cells were taken from a patients solid invasive ductal carcinoma of the 
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breast. All cell lines were purchased from the American Type Culture Collection and 
were kept according to the suppliers guidelines. The cells were split 2-3 times a week 
depending on confluence.  The culture media consisted of 500mL DMEM-F12, 75mL 
(15%) fetal bovine serum (FBS), 5mL (1%) penicillin/streptomycin (pen/strep) and 
0.01mg/mL (5mg) of insulin.   
 
SK-BR-3 
 SK-BR-3 is another human breast adenocarcinomal cell line that overexpresses 
HER-2.  However, these cells were taken from a metastatic site of a pleural effusion in 
the mammary gland of a patient with adenocarcinoma.  The culture media consists of 
500mL McCoys 5A Modified Medium, 50mL (10%) FBS and 5ml (1%) pen/strep. 
 
Human HER-2 non-over expressing cancer cell line 
MDA-468 
MDA-468 is a human breast adenocarcinoma cell line that does not overexpress 
the HER-2 protein.  This cell line was isolated from a pleural effusion of an African 
American female with metastatic adenocarcinoma of the breast.  The culture media 
consisted of 500mL RPMI 1640, 50mL (10%) FBS, and 5mL (1%) pen/strep. 
 
MCF-7 
 MCR-7 is a human breast adenocarcinoma cell line with normal HER-2 levels.  It 
was derived from a metastatic site of a Caucasian female.  The culture media consist of 
500mL DMEM, 50mL (10%) FBS and 5mL (1%) pen/strep. 
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Mouse neu+ overexpressing cancer cell line 
NT2.5 
NT2.5 is an FVB/n mouse cancer cell line that overexpresses the neu protein.  These 
cells were a kind gift from Dr. R. Todd Reilly.  The culture media is the same as the BT-
474 cell line. 
 
TUBO 
TUBO is a Balb/c cell line taken from a Balb-neuT mouse (neu+).  The culture media 
was the same as MCF-7.  These cells were a kind gift from Dr. John Morris. 
 
Mouse non-neu overexpressing cancer cell line 
TS/A 
TS/A is a Balb/c mouse cancer cell line that is neu- .  The culture media is the same as 
MDA-468. 
 
2.6 Antibody Binding 
  Flow Cytometry 
This procedure used is from that described in (21).  Cells were trypsinized and 
resuspended in 10 mL of appropriate culture media. The cells were counted by trypan 
blue staining.  A single cell suspension of about 1 ×106 cells per 100µL was placed in 
polysterene 5mL tissue culture tubes.  Initially primary (peptide) antibody concentrations 
of 1, 20, and 50µg were used to find optimum concentration.  The primary antibody was 
added to each test tube and gently vortexed.  The tubes were then incubated at 4°C for 2 
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hours.  The tubes were then washed with 1mL of ice cold PBS and spun at 1500rpm for 
5min at 4°C and decanted. This was repeated twice.  100µL of the secondary antibody, 
(anti-rabbit, anti-mouse or anti-human IgG-FITC conjugate) made up at 1:50, was added 
to each tube with minimal light exposure.  The tubes were then gently mixed by 
vortexing and incubated at 4°C for 30minutes and then re-washed 2 times as described 
above.  After incubation 500µL of 1% formaldehyde made in PBS was added to each 
tube.  The samples were analyzed by a Coulter ELITE flow cytometer.  About 10,000 
events were counted per sample for statistical significance.  Selection of healthy cells was 
gated by light scattered assessment before single-parameter histograms were drawn. 
 
HER-2 ELISA 
 Plates were coated overnight at 4°C with 100µL of 10µg/mL of Herceptin, 
washed four times with 0.1% Tween/PBS, and blocked with of 100µL of PBS-1% BSA 
for 4 hours on a rocker.  Plates were washed four times with 0.1% Tween/PBS.  Wells 
were then coated overnight at 4°C with 50µL of either PBS-1% BSA or SK-BR-3 cell 
lysate (1 x 108 cells in 20 mL lysis buffer).  Lysis buffer was composed of 1% Triton X-
100, 10% glycerol, 150 mM NaCl, 50 mM HEPES, 1.5 mM MgCl2, 1 mM EDTA, 10 
mM pyrophosphate, 100 mM NaF, 0.2 mM Na3VO4, 10 µg/ml aprotinin, 10 µg/ml 
leupeptin, and 1 mM PMSF.  Plates were washed four times with 0.1% Tween/PBS and 
serial dilutions of rabbit sera (starting at 1:100) were added and the plates were incubated 
for 2 hours on a rocker.  Antibody binding was detected using goat-anti rabbit IgG HRP. 
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2.7 Antibody Characterization 
Mouse Isotyping 
 FVB/n mouse sera from immunization of mice were typed using a Mouse Typer 
Sub-Isotyping Kit (Bio-Rad).  The manufacturers instructions were followed with the 
exception of substrate addition and stopping buffer reagent.  ABTS substrate and 1% 
SDS stopping buffer reagent as described above was used for this experiment.  
 
2.8  Antibody Inhibition of cell function and growth 
Cell Proliferation Assay 
 1×104 MCF-7 cells were plated in 96-well flat bottom plates and incubated at 
37°C overnight.  Growth media was then replaced with low-sera (1% FCS) growth media 
and cells incubated overnight.  Media was removed from the wells and replaced with 
antibody made up in 1% growth media.  Plates were incubated for one hour at 37°C, and 
then 10ng/mL HRG was added in 1% growth media.  Plates were incubated an additional 
72 hrs at 37°C before 5mg/mL of MTT was added to each well.  Plates were incubated 
for 2hr at 37°C, then 100µL extraction buffer (20% SDS, 50% dimethylformamide, pH 
4.7) was added to the plates.  Plates were incubated overnight at 37°C, and read on an 
Biorad microplate reader at 570nm with 655nm background subtraction.  % Lysis 
calculated as 100*(HRG Treated Cells-Antibody Treated Cells)/(HRG Treated Cells). 
 
HER-2 Phosphorylation Assay 
 MCF-7 cells were plated at 1x106 cells/well in 6-well plates and incubated 
overnight at 37°C.  Culture media was removed from the wells, and cells were washed 
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once with PBS.  1% culture media was added to the wells and plates were incubated 
overnight at 37°C.  Culture media was removed and the cell layer was washed with PBS.  
Next, 50µg of antibody in Binding Buffer (0.2% w/v BSA, RPMI medium with 10mM 
HEPES (pH 7.2)) was added to the wells and incubated at room temperature for one hour.   
5nM of HRG/well was added to the plate, and the plate was incubated an additional 10 
minutes at room temperature.  Binding Buffer was removed and the cell layer washed 
with PBS.  PBS was removed and 1mL lysis buffer (1% NP-40, 20mM Tris (pH 8.0), 
137mM NaCl, 10% glycerol, 2mM EDTA, 1mM Na3VO4, 10µg/mL aprotinin, 10µg/mL 
leupeptin) was added to the plate.  Plates were rocked at 4°C for 30min.  Lysates were 
removed from wells and spun at 13000× and supernatants were transferred into clean 
tubes.  Protein concentration of each sample was measured by Comassie plus protein 
assay reagent kit (Pierce).  Lysates were frozen immediately at -80°C and 
phosphorylation of HER-2/neu was determined by the DuoSet IC for Human Phospho-
ErbB2.  The manufacturers directions were followed (R&D Systems, Minneapolis, MN). 
 
2.9 Antibody dependent cell death 
Antibody dependent cell-mediated cytoxicity (ADCC) Assay 
 Procedures previously described in (22) were used to perform ADCC.  PBMCs 
were separated from heparinized whole blood from human donors by density gradient 
sedimentation using Ficoll.  The purified PBMCs were washed three times with culture 
medium and serially diluted into a 96-well plate to give effector:target ratios of 100:1, 
20:1, and 4:1.  On day two target cells are prepared and added to the effectors.  The target 
cell lines (BT474 and MDA468) were labeled with 200µCi of radioactive Na 51CrO4 and 
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incubated with 50µg of antibody for one hour at 37°C and then washed three times in 
cultured medium.   Targets were incubated with PBMCs without antibodies to determine 
nonspecific lysis.  The plates were incubated for four hours at 37°C.  The supernatants 
were then harvested and radioactivity was determined using a gamma counter. The 
percent lysis was determined by the following calculations:  %lysis = (A-B)/ (C-B) x 100, 
where A is 51Cr (cpm) from test supernatants, B is spontaneous release (51Cr from target 
cells without antibody treatment) and C is maximum release (51Cr from target cells lysed 
with 5%SDS detergent).  Triplicate measurements were performed on each treatment and 
were averaged prior to the calculation of percent lysis. 
 
3.0 In vivo Mouse Models 
Passive Immunotherapy: Double Transgenic Mice 
VEGF+/-Neu2-5+/- double transgenic mice were screened by PCR at 21 days old.  
On day 28 they were treated twice a week with 750µg purified IgG peptide induced rabbit 
antibodies for four weeks.  At 45 days old the mice were monitored for tumors twice a 
week until 69 days old when they were sacrificed (see Table2.2). 
 
Active Immunotherapy: Transgenic Mice 
 Neu2-5+/- transgenic mice were screened by PCR at 21 days old. On day 30 they 
were immunized with chimeric peptide and boosted every three weeks.  Blood was drawn 
by retro-orbital bleeding prior to immunization and every week after the first boost.  
Tumor onset in untreated mice is about 177 days.  At age 145 days mice were monitored 
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twice a week for tumor development until age 200 days when mice were sacrificed (see 
Table 2.2). 
 
Tumor Challenge  
NT2.5 Challenge 
 Mice were immunized with 0.1mg peptide emulsified in ISA720 with 100µg nor-
MDP.  Mice were boosted at 3 week intervals.  Blood was drawn prior to immunization 
and weekly after the first boost.  Ten days after the third immunization, mice were 
challenged with 3×106 NT2.5 cells.  Mice were monitored twice weekly for the presence 
of palpable tumors for a total of 24 days.  Tumors were measured with calipers in a 
blinded fashion and tumor volume calculated by the formula (long measurement x short 
measurement 2)/2 (see Table 2.2). 
 
TUBO Challenge 
 Mice were immunized with 0.1mg peptide emulsified in ISA720 with 100µg nor-
MDP.  Mice were boosted at 3 week intervals.  Blood was drawn prior to immunization 
and weekly after the first boost.  Fourteen days after the third immunization, mice were 
challenged with 1×105 TUBO cells.  Mice were monitored twice weekly for the presence 
of palpable tumors for a total of 35 days.  Tumors were measured with calipers in a 
blinded fashion and tumor volume calculated by the formula (long measurement x short 
measurement 2)/2 (see Table 2.2). 
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   Mouse strain                Genotype                      Treatment                   Tumor origin 
________________________________________________________________________ 
 
1. FVB/n                      Neu2-5+/-VEGF+/-       pure IgG antibodies             spontaneous 
2. FVB/n                           Neu2-5+/-                 peptide vaccine                  spontaneous 
3. FVB/n                         wild type                  peptide vaccine                 NT-2.5 challenge 
4. Balb/c                          wild type                  peptide vaccine                TUBO challenge 
________________________________________________________________________ 
 
Table.2.2. Mouse treatment. #1 passive immunotherapy  #2 active immunotherapy #3 and #4 tumor 
challenge. 
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Chapter 3 
Results 
 
3.1 Design and Characterization of Chimeric HER-2 Peptide Constructs 
 We relied on the crystal structure of HER-2 complexed with pertuzumab to 
predict the B-cell epitope (Fig.2.1)(18).  The HER-2 B-cell epitope was co-linearly 
synthesized as a chimeric peptide containing a promiscuous T-helper cell epitope (a.a. 
288-302) from MVF at the amino terminus end.  The T-helper epitope from MVF has 
been shown to help bypass the haplo restrictive immune response in humans (23).  The 
cyclized chimera contained a cysteine bridge in the B-cell epitope to mimic the native 
structure of the HER-2 protein.  The chimeric peptides contained a four-residue (GPSL) 
linker between the T-helper and B-cell epitope.  The flexible nature of the linker allows 
the T-helper and B-cell epitope to fold independently into their native secondary 
structures (Table 3.1). 
 
Table 3.1 Synthetic peptide vaccines characteristics 
Chimeric peptide constructs                             Molecular Weight               Disulfide Bridge          TH  epitope      GPSL linker          
 
MVFHER-2 (pertuzumab loop) NC                       5759.72                   No                            Yes                       Yes 
 
MVFHER-2(pertuzumab loop) Cyc          5757.72                                 Yes                          Yes                       Yes 
 
NC- non-cyclized ; Cyc- cyclized  
 
Mass spectroscopy is the technique used to identify the molecular mass of 
purified peptide.  The matrix-assisted laser desorption/ionization (MALDI) mass 
spectroscopy technique was used.  The peptide is dissolved in a solvent and a UV 
absorbing agent is added.  In a vacuum the solvent evaporates and the peptide is 
dispersed in a matrix of the UV absorbing compound.  The sample is then hit with a UV 
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laser in the 330-360nm range.  The UV absorbing material absorbs the energy from the 
laser and passes the energy onto the peptide, which then evaporates.  The matrix material 
interacts with the peptide in such away that the peptide becomes charged ions.  Electrical 
force is applied on each peptide molecule that has a different molecular weight.  The 
output of the mass spectrometer plots the relative intensity vs. the mass to charge ratio, 
which is usually equivalent to the molecular weight. Theoretical molecular weight and 
observed molecular weight should be in agreement (Fig3.1).  
 
Fig. 3.1 Mass spectrometry reading for MVFHER-2(pertuzumab loop) Cyc 
 
OSU-1117MVFEB, in 100ul, load 5ul, Q-TOF CapLC-MS 07-Feb-2005
4000 4200 4400 4600 4800 5000 5200 5400 5600 5800 6000 6200 6400 6600 6800 7000 7200 7400 7600 7800 8000
mass0
100
%
QT07551  703 (25.148) M1 [Ev-113989,It10] (Gs,0.750,676:2100,2.00,L33,R33); Cm (698:704) TOF MS ES+ 
5.83e35758.0005
5342.0005
4318.0000 4608.0000 5176.0005
7406.00056710.0005
5982.0005 6346.0005
7108.0005 7862.0005
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The molecular weight of the non-cyclized construct (not shown) is 5,759.72 and 5,757.72 
for the cyclized construct.  The difference arises due to the disulfide bond in the cyclized 
construct which results in the loss of two hydrogen atoms.  To determine if the disulfide 
bond was correctly formed, both constructs were treated with PEO-Maleimide.  PEO-
Maleimide attacks free sulfhydryl groups and therefore can be used to determine the 
completion of disulfide pairing by ESI-MS.  Therefore, the linear peptide with two free 
Cys (SH) group shows the addition of PEO groups (Mr =525.62), while the cyclized 
peptide shows no addition of PEO-maleimide and molecular weight of the peptide 
remains the same (see Fig 3.2). 
                          
Fig 3.2 Maleimide treated mass spectrometry reading a. HER-2(pertuzumab loop) Cyc b. HER-2 
(pertuzumab loop) NC 
 
The secondary structure of the B-cell epitope was analyzed by circular dichroism 
(CD) spectroscopy.  CD was used characterize the secondary and tertiary structures of the 
protein.  In the far-uv spectral region (190-250nm) the secondary structure can be 
evaluated.  At these wavelengths the peptide bond is the chromophore and a signal arises 
when it is detected in a regular, folded environment.  Protein secondary structures (α-
helix, β-sheet, random coil) give rise to unique CD spectra.  Analysis of the far-uv CD 
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spectrum can give an approximate fraction of each secondary structure present in the 
protein.  The CD spectrum of a protein in the near-uv spectral region (250-350nm) is 
sensitive to tertiary structural features. If the protein does not contain a well defined 
three-dimensional structure the signals in the near-uv region will be close to zero.   
The B-cell epitope analyzed has a β-sheet secondary structure in the native HER-2 
protein.  The CD spectra from 190-290nm of both chimeric peptides in water were 
analyzed (Fig 3.3). 
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Fig 3.3.Circular Dichroism spectrum of HER-2(pertuzumab loop) Cyc and HER-2(pertuzumab loop) NC at 
100µM 
 
Non-cyclized peptide showed CD ellipticity minima around 206nm and the cyclized 
peptide showed minima around 209nm.  These minima are characteristic of beta sheet 
secondary structures in the B-cell epitopes similar to the native protein.  In the near uv 
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region (250-290nm) of both peptides give signals near zero indicating their lack of well 
defined three-dimensional conformations. 
The cross-reactivity ELISA analyzed antibody binding of both the cyclic and 
linear structures of the synthetic HER-2 B-cell epitope.  This experiment allowed us to 
determine how significant a role the disulfide bond in the B-cell epitope played in 
antibody recognition.  The antibodies were tested against the peptide immunogens (Fig. 
3.4a and c.) and the non-cyclized and cyclized HER-2 B-cell epitopes (Fig.3.4b and d).  
Both cyclized and non-cyclized antibodies recognized the linear and cyclized chimeric 
peptides as well as both B-cell epitope constructs.  This shows that the structural 
difference, removal of the disulfide bridge, in the synthetic B-cell epitope does not 
significantly inhibit antibody binding. The cyclized antibodies had a slightly higher 
affinity for binding to both chimeric constructs than the non-cyclized antibodies.  The 
affinity of the antibodies to the peptide was nearly identical to that of the B-cell epitope, 
this demonstrates the inability of the antibodies to significantly bind to the MVF T-helper 
epitope that is incorporated in the synthetic peptide vaccines.   
  a.                                                                            
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Fig.3.4. Cross-reactivity ELISA antibody affinity to chimeric peptides and B-cell epitopes. a. Antibody 
titers against the MVFHER-2 (pertuzumab loop) NC peptide construct b. Antibody titers against non-
cyclized B-cell epitope c. Antibody titers against the MVFHER-2 (pertuzumab) Cyc peptide construct d. 
Antibody titers against cyclized B-cell epitope 
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3.2 Immunogenicity of the Peptide Constructs in outbred Rabbits 
 Both HER-2 peptide constructs elicited high titered antibody responses in pairs of 
immunized outbred rabbits (Fig.3.5).  The rabbits were bled every week for 10 weeks and 
boosted every third week after the initial immunization.  The NC peptide was more 
immunogenic between the two constructs and elicited slightly higher antibody titers.  The 
direct ELISA experiment provides a way to measure the anti-peptide antibody 
concentration in sera. 
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Fig. 3.5. Direct ELISA. Antibody titers in immunized outbred rabbits. 1y+3w indicates the titers obtained 
from sera 3 weeks (3w) after the first (1y) immunization. 
 
3.3 Antibody Recognition of Native HER-2 Protein 
 Synthetic peptides elicit protein-reactive antibodies if the structural characteristics 
of the peptides correlate with the native protein.  In order to determine the ability of the 
antibodies induced by the chimeric HER-2 peptide constructs to recognize the native 
HER-2 protein, the cross-reactivity of the antibodies was analyzed by flow cytometry, 
competitive ELISA assays and the HER-2 ELISA assays.  Flow cytometry gives 
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information about a cells physical characteristics based on the way it absorbs or reflects 
light.  Antibodies bound to cells are shown by a shift in the peaks of the histogram.  The 
more rightward shift in a peak corresponds to increased binding of the anti-peptide 
antibodies. Analysis by flow cytometry showed binding of the induced antibodies from 
both peptide constructs to a HER-2 overexpressing cell line (BT474).  The cyclized 
construct induced antibodies showed slightly more than binding than the non-cyclized 
construct induced antibodies (Fig.3.6 a).  The peptide induced antibodies were also tested 
against a neu overexpressing mouse cell line (NT2.5) to determine their ability to bind 
the HER-2 homolog neu (Fig. 3.6 b).  This information is useful to determine whether or 
not to pursue in vivo mouse studies.   
a.       b. 
        
                                                  
Fig. 3.6. a. Flow cytometry. Analysis of the binding of non-cyclized and cyclized rabbit induced antibodies 
to BT-474 (HER-2 overexpressing cells). 
 
  
 The HER-2 ELISA assed the ability of the anti-peptide antibodies to recognize 
and directly bind the native HER-2 protein.   The high optical density (OD) 
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measurements correlate with a greater degree of antibody binding (Fig. 3.7).  The Cyc 
antibodies showed slightly better binding of the native HER-2 protein. 
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Fig.3.7 HER-2 ELISA.  Antibody recognition of the native HER-2 protein. 
 
3.4 Antibody Characterization 
 Several classes of mouse antibodies (immunoglobulins) exist and they are all 
structurally different depending on the heavy chain composition.  Antibodies can kill 
tumor cells by engaging other cells of the immune system.  IgG1, and IgG2 (both IgG2a 
and IgG2b) isotype antibodies are known for assisting in antibody dependent cell 
mediated cytotoxicity (cell death) using human peripheral blood mononuclear cells 
(PBMC) as effectors.  The mouse isotype ELISA analyzed the light and heavy chains of 
the peptide induced antibodies (Fig.3.8). This experiment is convenient for identifying 
mouse immunoglobulin class and subclasses of IgG1, IgG2a, IgG2b, IgG3, IgM and IgA as 
well as the light chain isotype of either κ or λ.  The serum tested was from the different 
mouse bleeds. The light chain isotype of both the Cyc and NC antibodies was κ (not 
shown).   
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Fig. 3.8  Mouse Isotype ELISA. Determination of immunoglobulin class and sub-class. a. Cyc antibodies 
b. NC antibodies 
 
Most of the antibodies typed from both peptide constructs were IgG class and specifically 
of IgG1 and IgG2a subclasses.   
 
3.5 Antibody Inhibition of Cell Function and Growth 
The ability of the peptide induced antibodies to effect tumor growth was tested in 
vitro by the MTT cell proliferation assay using human HER-2 normal expressing MCF-7 
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cells. Both Cyc and NC antibodies were capable of reducing the proliferation of MCF-7 
cells in the presence of 10ng/mL heregulin (a HER-3 ligand) compared to presera treated 
cells (Fig3.9).  
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Fig. 3.9 Cell Proliferation Assay. Percent inhibition of HER-2 overexpressing human tumor cells (MCF-7). 
 
 The HER-2 phosphorylation assay analyzed the amount of phosphorylated HER-
2 present after reaction with the anti-peptide antibodies (Fig.3.10).  Preventing 
phosphorylation of HER-2 is a way to stop signaling mechanisms.  After HER-2 
dimerizes, transphosphorylation of the dimers tails occurs which initiates a signaling 
network involved in cell proliferation and differentiation, which can lead to tumor 
development.  The prevention of phosphorylation of HER-2 by the peptide induced 
antibodies results in indirect inhibition of tumor growth.  Both peptide induced antibodies 
showed the ability to inhibit phosphorylation.  AG 825, a phosphorylation inhibitor of 
HER-2, was used as a positive control and the normal rabbit IgG antibodies were the 
negative control.  The NC antibodies had a slightly higher percent of inhibition compared 
to the Cyc antibodies. 
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Fig.3.10 HER-2 phosphorylation Assay. Percent Inhibition of HER-2 phosphorylation in vitro. 
 
3.6 Antibody Dependent Cell Death 
The antibody-dependent cell mediated cytotoxicity assay (ADCC) shows the 
ability of the peptide induced antibodies to successfully cause cell lysis (Fig.3.11).  The 
peptide induced IgG antibodies attach to the extracellular domain of the HER-2 protein 
and are recognized by the Fc receptor of natural killer (NK) cells leading to its activation 
and thus release of cytokines.  These cytokines in return trigger events that result in lysis 
of the antibody-coated cells.  The control IgG antibodies used for Herceptin were normal 
human IgG antibodies and for the anti-peptide antibodies normal rabbit IgG.  In 
comparison to the percent lysis due to effectors and targets only the anti-peptide 
antibodies show antibody specific lysis at each effector target ratio. 
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Fig 3.11 ADCC. Cyc and NC peptides antibody-dependent cell mediated cytotoxicity of 51Cr-labeled 
mammary tumor target cell line BT474 assayed in presence of human PBMCs. (Effector: Target) 
 
3.7 In vivo Mouse Models 
 Passive and active immunotherapeutic experiments were carried out in transgenic 
mice.  Transgenic mouse models express mammary tumors similar to human breast 
cancer.  Experimentation with these mouse models mimic tumor growth in a clinical 
setting.  These genetically engineered mice develop spontaneous tumors similar to cancer 
patients.   Spontaneous tumors effect surrounding tissue and create genetic changes due 
to tumor growth.  Double transgenic (VEGF+/- Neu2-5+/-) were tested by passive 
immunotherapy due to rapid tumor onset in these mice. These mice develop tumors 
around the age of 55 days due to the overexpression of VEGF protein.  VEGF is a gene 
that causes angiogenesis (new vessel development), this in turn helps nurture the 
developing tumor, which results in early tumor development.  These mice were passively 
treated with purified IgG rabbit antibodies to analyze the tumor inhibitory characteristics 
of the peptide induced antibodies.  VEGF+/- Neu2-5+/- mice injected with purified IgG 
MVFHER-2(pertuzumab loop)Cyc or MVFHER-2(pertuzumab loop)NC antibodies 
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showed a statistically significant reduction in tumor size compared to mice treated with 
presera antibodies (p= 0.0001 and p=0.0008). This shows the capabilities of these 
antibodies to directly inhibit tumor growth (Fig. 3.12). 
 
Fig 3.12 Passive immunotherapy. VEGF+/- Neu2-5+/- double transgenic treated with purified IgG 
MVFHER-2(pertuzumab loop) Cyc or NC or presera antibodies. 
 
  Neu2-5+/- mice were used to test the in vivo anti-tumor effects of the synthetic 
peptide vaccine.  These mice develop tumors around day 177 days. The mice vaccinated 
with the target peptide showed a delayed onset of tumor and in general had a lower tumor 
volume compared to the pre-treated mice (Fig 3.13).  These preliminary results and 
studies show the ability of the synthetic vaccines to enhance the mouse immune system 
and affect tumor development.  However, ongoing studies are being conducted in order to 
reach statistical significance. 
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Fig 3.13 Active immunotherapy. Neu2-5+/- transgenic mice treated with MVFHER-2(pertuzumab loop) 
Cyc or NC chimeric peptide construct. (F2D#3, F2E#1, F2E#2, F2J#2 and F2J#3 are names of the mice) 
 
Tumor challenge 
  Immunizing the mice with the synthetic peptide allows the mice time to mount 
an immune response.  Their immune system will have already built up a defense before 
the mice are challenged with tumor cells.  The mice are challenged with tumor cells that 
come from the same strain of mouse (same genotype).  If the mice were challenged with 
tumor cells that are genotypically different the immune system would recognize the 
tumor cells as foreign antigens and cause the mouse to immediately reject the tumor cells 
and not allow tumor development.  Tumor challenged mice develop tumors different 
from spontaneous tumors in that there is not as much genetic manipulation in the 
surrounding tissues and the tumor is of one cell type as opposed to multiple types.  In the 
NT2.5 tumor challenge, FVB/n mice were challenged with tumor cells (NT 2.5) from the 
same mouse strain 10 days after their last immunization.  The mice immunized with the 
synthetic vaccine elicited high titered antibody responses prior to the tumor challenge 
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(Fig.3.14a).  Mice immunized with either the Cyc or NC peptide showed a statistically 
significant reduction in tumor volume compared to mice treated with MVF (p= <0.001 
and p= 0.002) (Fig3.14b).  The synthetic MVFHER-2(pertuzumab loop) Cyc vaccine 
demonstrated an overall lower tumor volume in comparison to the linear construct.   
 
 
Fig.3.14 NT2.5 tumor cell challenge in FVB/n mice. a. Antibody response to synthetic vaccines in mice 
prior to tumor challenge. b. NT2.5-tumor challenge results. 
 
An additional tumor challenge experiment with TUBO cells was performed.  
Mice immunized with either peptide construct showed high antibody titers prior to the 
tumor challenge (Fig.3.15a)  Balb/c mice were challenged with neu overexpressing 
TUBO cells from the same mouse strain 14 days after the last immunization (Fig. 3.15b).  
The mice immunized with the MVFHER-2 (pertuzumab loop) Cyc or MVFHER-2 
(pertuzumab loop) NC peptide showed a statistically significant reduction in tumor 
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growth compared to MVF immunized mice (p=0.0007 and p= 0.0002 respectively).  In 
this study the synthetic NC peptide vaccine demonstrates higher tumor inhibitory effects.  
  
Fig 3.15 TUBO tumor challenge in Balb/c mice. a. Antibody response in mice to synthetic vaccines prior to 
challenge. 2y+3 indicates blood drawn 3 weeks after second boost. b. TUBO challenge results. 
 
Both tumor challenge studies confirm the ability of each synthetic peptide vaccine to 
decrease tumor growth in HER-2/neu overexpressing tumor cells in vivo.
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Chapter 4 
Discussions 
 The overexpression of HER-2 in many cancers, its low levels of expression in 
normal adult tissues, and the surface exposed extracellular domain make it an ideal target 
for immunotherapy.  Since the crystal structure of HER-2 complexed with the anti-HER-
2 monoclonal antibody pertuzumab has been solved (18), it is now possible to directly 
asses antigenic sites on HER-2 based on this crystal structure, such as, the pertuzumab 
loop region.  It is imperative that peptides are modeled like the native conformation of the 
target protein in order for their antibodies to bind the target antigen with a high enough 
affinity to be biologically significant.   In this study we systematically assessed the 
biological effects of two synthetic peptide vaccines that contained an antigenic HER-2 B-
cell epitope, in the native cyclized structural form and in the linear form.  The focus of 
this thesis is the design of peptide vaccines that against the HER-2/neu dimerization loop.  
We hypothesize that developing a vaccine that incorporates residues pertuzumab loop 
from the HER-2 dimerization loop will inhibit tumor growth by eliciting antibodies that 
sterically hinder the dimerization loop of the HER-2 protein.  
 Our approach involved the de novo design of peptide vaccines that focused on 
maintaining the native protein structure while introducing a minute structural change, 
removal of the disulfide bond, to analyze the biological effect.  Previous work in different 
model systems demonstrated that the incorporation of promiscuous T-helper (TH) epitope 
derived from non-human molecules can be used to help elicit high-titered antibodies that 
recognize the native protein in an outbred population (24).  The synthetic vaccine design 
incorporated a promiscuous TH epitope, a GPSL linker and the HER-2 B-cell epitope 
 48 
 
(pertuzumab loop).  The chimeric peptides were synthesized co-linearly using Fmoc-/t-
But chemistry.  An intramolecular disulfide bond between two cysteine residues of the B-
cell epitope was formed in the cyclized construct.   
 An important characteristic of vaccines is the ability to generate protection in 
outbred populations.  Therefore, we analyzed the immunogenicity of each chimeric 
peptide in outbred rabbits and eventually in inbred FVB/n and Balb/c mice as tumor 
challenge models.  The MVFHER-2(pertuzumab loop) NC vaccine elicited slightly 
higher antibody titer responses than the cyclic vaccine.  However, this didnt correlate to 
superior anti-tumor inhibitor effects of the linear construct in comparison the cyclic 
construct.  A successful peptide vaccine is able to generate antibodies that recognize and 
bind the native protein.  We used flow cytometry to assess the ability of the antibodies 
generated from our synthetic peptide vaccines to recognize the native protein.  Flow 
cytometry indicated that the antibodies to the cyclized peptide construct showed better 
binding to the HER-2 overexpressing BT474 cells than the linear construct. The HER-2 
ELISA showed similar results of the Cyc antibodies binding better to the native HER-2 
protein.  Even though the Cyc antibodies showed better binding to the native structure of 
HER-2, this did not correlate to consistently better indirect and direct anti-tumor effects.   
The cross reactivity ELISA established the ability of both peptide induced 
antibodies to cross react with the cyclic and linear HER-2 B-cell epitope constructs and 
immunogen peptides.  These results confirm the conservation of the antibody binding 
region in the cyclic B-cell epitope and the specificity of the antibodies to the B-cell 
epitope and not other components of the vaccine.   
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 The ability of the peptide induced antibodies to inhibit HER-2/neu dimerization 
by steric hindrance of the dimerization loop and indirectly limit cellular growth was 
assessed by the HER-2 phosphorylation assay.  The Cyc antibodies showed a 17% 
inhibition of phosphorylation of the HER-2 protein, whereas the NC antibodies showed 
an 18% inhibition.  Therefore, these antibodies are capable of directly affecting the 
phosphorylation of HER-2 via blockage of the dimerization loop.  This displays the 
potential of these antibodies to disrupt downstream signaling of the HER-2 homo- or 
heterodimer that is responsible for cell proliferation.  Direct inhibition of cell growth was 
studied by an in vitro cell proliferation assay. The cell proliferation assay demonstrated 
the ability of both peptide induced antibodies to limit growth of human cancer cells in 
vitro compared to cells treated with only normal rabbit IgG antibodies.  Indirect anti-
tumor effects of the peptide antibodies were shown in ADCC.  The NC antibodies 
showed an increase in cytotoxicity against HER-2 overexpressing cells compared to the 
cyclized construct as measured by ADCC.  These findings show the ability of both 
antibodies to kill tumor cells by mediating cytotoxic effects in natural killer cells. 
 In the transgenic mouse models, direct tumor growth inhibition was slightly better 
in mice passively treated with the purified cyclized IgG peptide antibodies or actively 
treated with the cyclized peptide itself as opposed to ones treated with the linear 
antibodies or peptide.  Statistical significance was obtained in these experiments.  The p-
value is a statistic term that indicates the probability that the difference between groups 
during an experiment happened by chance.  The lower the p-value the more likely the 
difference in tumor size was due to treatment.   Mice passively immunized with Cyc or 
NC antibodies showed a statistically significant smaller average tumor size compared to 
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pre antibody treated mice (p=0.0001 and p=0.0008).  The tumor challenge mice treated 
with the synthetic peptide vaccine have displayed lower tumor volumes that are 
statistically significant.  In the NT2.5 challenge, mice immunized with MVFHER-2 
(pertuzumab loop) Cyc or MVFHER-2(pertuzumab loop) NC showed a statistically 
significant reduction in tumor volume compared to mice treated with MVF alone (p= 
<0.001 and p= 0.002).  The TUBO challenge showed that mice immunized with the 
MVFHER-2 (pertuzumab loop) Cyc or MVFHER-2 (pertuzumab loop) NC showed a 
statistically significant reduction in tumor growth compared to MVF immunized mice 
(p=0.0007 and p= 0.0002 respectively). This shows the ability of both peptide vaccines to 
successfully limit tumor cell development in vivo.   
 This study has shown that subunit peptide vaccines can target immune responses 
to biologically active epitopes.  The ability to focus the immune response is particularly 
relevant to HER-2, where antibody interaction with specific sites has the potential to 
sterically hinder dimerization and thus limit cellular proliferation.  In this thesis the 
peptide vaccines tested were capable of eliciting HER-2 specific antibodies in an outbred 
population with the ability to inhibit development of HER-2 overexpressing cancers by 
blocking homo- and heterodimerization.
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Chapter 5 
Conclusions 
 The revolutionary approach of using peptide vaccines to treat cancer proves 
promising for future endeavors.  The findings of this thesis show potential for designing 
vaccines that target the HER-2 oncoprotein.  Further testing of the synthetic peptide 
vaccines direct and indirect anti-tumor effects is necessary to establish clinical 
significance in the data.  Future work includes the goal of obtaining FDA approval to 
move into clinical trial phase.  Continual evaluation and testing of different antigenic 
sites on the HER-2 protein for potential synthetic peptide vaccines proves useful to 
developing an effective cancer treatment.  Other studies could include a multi-epitope 
approach to vaccine design.  The incorporation of two or three B-cell epitopes may prove 
to be a better more effective vaccine design.  For example, a vaccine that targets a HER-2 
antigenic site and incorporates the VEGF epitope can create an immune response that 
causes inhibition of tumor development two ways. First, seeking to prevent dimerization 
of HER-2 that leads to signaling and cell growth, and secondly, creating antibodies that 
effectively bind the VEGF protein and cut off blood supply to the tumor, which is vital 
for tumor growth.  The use of multiepitope vaccines incorporating both Herceptin and 
pertuzumab epitopes in combination with a HER-2 vaccine that prevents dimerization 
could suppress tumor development completely.  In this thesis the design of a synthetic 
peptide vaccine targeting the HER-2/neu dimerization loop and incorporating both T and 
B-cell epitopes proves useful in inhibiting the growth of HER-2/neu overexpressing 
tumor cells. 
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